Many pharmacological PI3K/Akt inhibitors have been extensively evaluated as potential anti-cancer agents, which can abolish the capability of cancer cells to extend their life span against anti-cancer pressures such as cellular immune response and inflammation. The gene discussed is AKT1; the disease is cancer.